Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
41.42
+2.08 (5.29%)
At close: Mar 27, 2026
Market Cap49.44B +2.0%
Revenue (ttm)7.17B -3.5%
Net Income669.02M -36.1%
EPS0.78 -35.6%
Shares Outn/a
PE Ratio73.89
Forward PE36.21
Dividend0.32 (0.89%)
Ex-Dividend DateJun 12, 2025
Volume2,181,754
Average Volume1,557,878
Open39.54
Previous Close39.34
Day's Range39.24 - 41.80
52-Week Range22.30 - 60.60
Beta0.82
RSI45.61
Earnings DateMar 30, 2026

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3347

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY Financial Statements